+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Active Pharmaceutical Ingredient (API) Market

  • PDF Icon

    Report

  • 150 Pages
  • January 2022
  • Region: Global
  • Qualiket Research
  • ID: 5530684
UP TO OFF until Dec 24th 2022
Two central components in the making of a drug are API’s and Excipients. API is the main component from which the drug is manufactured, however the excipient is the ingredient which isn’t the drug, but acts as a medium that facilitates the body to consume the drug, such as lactose or mineral oil in a pill.





Impact of the COVID-19


The surge in corona cases worldwide has played an essential role in active pharmaceutical ingredient manufacturers' development over the forecast period. The administration has done a molecule-by-molecule charting of active pharmaceutical ingredients (APIs) imported from China to uplift domestic construction and imports from third party suppliers in sight of the supply chain disruptions due to the COVID-19 pandemic. Pandemic has added a further difficulty as governments worldwide decided to boycott APIs manufactured in China.

Regional Analysis


North America currently leads the market for active pharmaceutical ingredients and is anticipated to continue its stronghold for a few more years due to the growing incidences of disease and rising aging population. The European regional active pharmaceutical ingredient market is anticipated to account for a second principal market share through the forecast period. The Asia Pacific active pharmaceutical ingredient market is assessed to be the fastest encouraging region in the worldwide active pharmaceutical ingredient market because of the commonness of quickly emerging markets are developing as core hubs for outsourcing drug manufacturing.

Key Development


In 2020, Pfizer (US) signed a multiyear agreement with Gilead Sciences to manufacture and supply Gilead’s antiviral drug (Remdesivir) for the treatment of COVID-19.

In 2020, Novartis (Switzerland) acquired Aspen’s Japanese operations to strengthen its position in the global generics and off-patent medicines market. Novartis also entered into a manufacturing and supply agreement with Aspen.

In April 2020, Boehringer Ingelheim (Germany) acquired Northern Biologics, which focuses on therapeutic antibodies targeting the tumor microenvironment. This acquisition broadened Boehringer Ingelheim’s oncology product portfolio.

Key Players


Some of the key players operating in Active Pharmaceutical Ingredient (API) Market are Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, Cipla, Inc., F. Hoffmann-La Roche AG, Pfizer Inc., Merck & Co., Teva Pharmaceutical Industries Ltd.

Market Taxonomy


By Business Mode

  • Captive API
  • Merchant API

By Synthesis Type

  • Synthetic
  • Biotech

By Type of Drug

  • Generic
  • Branded

By Application

  • Cardiology
  • Pulmonology
  • Oncology
  • Ophthalmology
  • Neurology
  • Orthopedic
  • Other Applications

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Frequently Asked Questions about the Active Pharmaceutical Ingredient (API) Market

What is the estimated value of the Active Pharmaceutical Ingredient (API) Market?

The Active Pharmaceutical Ingredient (API) Market was estimated to be valued at $187.3 billion in 2017.

What is the growth rate of the Active Pharmaceutical Ingredient (API) Market?

The growth rate of the Active Pharmaceutical Ingredient (API) Market is 2.9%, with an estimated value of $248.3 billion by 2027.

What is the forecasted size of the Active Pharmaceutical Ingredient (API) Market?

The Active Pharmaceutical Ingredient (API) Market is estimated to be worth $248.3 billion by 2027.

Who are the key companies in the Active Pharmaceutical Ingredient (API) Market?

Key companies in the Active Pharmaceutical Ingredient (API) Market include Aurobindo Pharma Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Boehringer Ingelheim International GmbH, Cipla Inc., F. Hoffmann, La Roche AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.

Table of Contents

1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Active Pharmaceutical Ingredient (API) Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Active Pharmaceutical Ingredient (API) Market, By Business Mode
5.1 Y-o-Y Growth Comparison, By Business Mode
5.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
5.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Business Mode
5.3.1 Captive API
5.3.2 Merchant API
6 Active Pharmaceutical Ingredient (API) Market, By Synthesis Type
6.1 Y-o-Y Growth Comparison, By Synthesis Type
6.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Synthesis Type
6.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
6.3.1 Synthetic
6.3.2 Biotech
7 Active Pharmaceutical Ingredient (API) Market, By Type of Drug
7.1 Y-o-Y Growth Comparison, By Type of Drug
7.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Type of Drug
7.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
7.3.1 Generic
7.3.2 Branded
8 Active Pharmaceutical Ingredient (API) Market, By Application
8.1 Y-o-Y Growth Comparison, By Application
8.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Application
8.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
8.3.1 Cardiology
8.3.2 Pulmonology
8.3.3 Oncology
8.3.4 Ophthalmology
8.3.5 Neurology
8.3.6 Orthopedic
8.3.7 Other Applications
9 Active Pharmaceutical Ingredient (API) Market, By Region
9.1 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Region
9.2 Active Pharmaceutical Ingredient (API) Market Share Analysis, By Region
9.3 Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Region
10 North America Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
10.1 Introduction
10.2 North America Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
10.3 North America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
10.4 North America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
10.4 North America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
10.5 North America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Country
10.5.1 U.S.
10.5.2 Canada
10.5.3 Mexico
11 Europe Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
11.1 Introduction
11.2 Europe Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
11.3 Europe Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
11.4 Europe Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
11.4 Europe Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
11.5 Europe Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Country
11.5.1 Germany
11.5.2 France
11.5.3 UK
11.54. Rest of Europe
12 Asia Pacific Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
12.1 Introduction
12.2 Asia Pacific Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
12.3 Asia Pacific Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
12.4 Asia Pacific Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
12.4 Asia Pacific Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
12.5 Asia Pacific Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Country
12.5.1 China
12.5.2 Japan
12.5.3 India
12.5.4. Rest of Asia Pacific
13 Latin America Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
13.1 Introduction
13.2 Latin America Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
13.3 Latin America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
13.4 Latin America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
13.4 Latin America Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
13.5 Latin America Active Pharmaceutical Ingredient (API) Market Size and Forecast, Country
13.5.1. Brazil
13.5.2. Rest of Latin America
14 Middle East Active Pharmaceutical Ingredient (API) Market Analysis and Forecast (2021-2027)
14.1 Introduction
14.2 Middle East Active Pharmaceutical Ingredient (API) Market Share Analysis, By Business Mode
14.3 Middle East Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Synthesis Type
14.4 Middle East Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Type of Drug
14.4 Middle East Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Application
14.5 Middle East Active Pharmaceutical Ingredient (API) Market Size and Forecast, By Country
14.5.1. Saudi Arabia
14.5.2. UAE
14.5.3. Egypt
14.5.4. Kuwait
14.5.5. South Africa
15 Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16 Company Profiles
16.1 Aurobindo Pharma Limited
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Sun Pharmaceutical Industries Ltd.
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 Dr. Reddy’s Laboratories Ltd.
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Boehringer Ingelheim International GmbH
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Cipla Inc.
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 F. Hoffmann-La Roche AG
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 Pfizer Inc.
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies
16.8 Merck & Co.
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies
16.9 Teva Pharmaceutical Industries Ltd.
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aurobindo Pharma Limited
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • Merck & Co.
  • Teva Pharmaceutical Industries Ltd